Latest news with #VrindavanGlobal
Time of India
4 days ago
- Health
- Time of India
3 drugs fail quality test in CG, samples declared substandard
Raipur: Three drug samples collected from various districts in Chhattisgarh were declared substandard following inspections by the food and drug administration and laboratory testing. This is part of an ongoing drive to ensure that quality medicines are available to the public. According to departmental sources, 34 drug samples were collected from districts including Raipur, Bilaspur, Durg, Sakti, Rajnandgaon, Kondagaon, and Surajpur. These samples were sent to the State Drug Testing Laboratory in Raipur. After testing in May 2025, three medicines failed to meet quality standards. The substandard drugs include Vildamed Tablet (Batch No. VGT 242068A), manufactured by Vrindavan Global, Solan, Himachal Pradesh; Rifliwe M Tablet (Batch No. HG 24080598), manufactured by I Heal Pharmaceuticals, Baddi, Himachal Pradesh; and Donlocare DS Suspension (Batch No. DCN-002), manufactured by Quixotic Pharma, Mohali, Punjab. These medicines are commonly used to treat diabetes, fever, and infections. The department is taking action against the concerned manufacturers and distributors in accordance with regulations, said a departmental spokesperson. State health minister Shyam Bihari Jaiswal said, "There will be no compromise with public health. Strict action will be taken against those selling or distributing substandard medicines. Our govt is committed to ensuring high-quality healthcare services in the state. All drug retailers have been instructed to sell only recognised and certified medicines." In a related development, teams of drug inspectors are conducting continuous raids on medical stores across the state to prevent the misuse of narcotic drugs. Work is also progressing rapidly to equip all medical establishments with CCTV cameras, as per govt directives.
Time of India
4 days ago
- Health
- Time of India
Five drugs fail quality test in Chhattisgarh as crackdown on narcotics, tobacco continues
RAIPUR: Five drug samples collected from various districts in Chhattisgarh have been declared substandard following inspections by the Food and Drug Administration and subsequent laboratory testing. This comes as part of an ongoing drive to ensure that quality medicines are available to the public. According to departmental sources, 34 drug samples were collected from districts including Raipur, Bilaspur, Durg, Sakti, Rajnandgaon, Kondagaon, and Surajpur. These samples were sent to the State Drug Testing Laboratory in Raipur. After testing in May 2025, three medicines were found to have failed to meet quality standards. The substandard drugs include Vildamed Tablet (Batch No. VGT 242068A), manufactured by Vrindavan Global, Solan, Himachal Pradesh; Rifliwe M Tablet (Batch No. HG 24080598), manufactured by I Heal Pharmaceuticals, Baddi, Himachal Pradesh; and Donlocare DS Suspension (Batch No. DCN-002), manufactured by Quixotic Pharma, Mohali, Punjab. These medicines are commonly used to treat diabetes, fever, and infections. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Alarma con cerradura inteligente gratis en Cádiz, instalación en un día Securitas Direct Alarma Ver oferta Undo The department is taking action against the concerned manufacturers and distributors in accordance with regulations, said a departmental spokesperson. State Health Minister Shyam Bihari Jaiswal stated, 'There will be no compromise with public health. Strict action will be taken against those selling or distributing substandard medicines. Our government is committed to ensuring high-quality healthcare services in the state. All drug retailers have been instructed to sell only recognised and certified medicines.' In a related development, teams of drug inspectors are conducting continuous raids on medical stores across the state to prevent the misuse of narcotic drugs. Work is also progressing rapidly to equip all medical establishments with CCTV cameras, as per government directives. The Food and Drug Administration has appealed to the public to check the quality and expiry date of medicines before purchasing and to report any suspicious drugs to the department.
